SEATTLE, Oct. 04, 2024 (GLOBE NEWSWIRE) -- (OTC Pink: KANT) , a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune ...
Some results have been hidden because they may be inaccessible to you